Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.10USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$14.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
176,036
52-wk High
$18.00
52-wk Low
$7.23

Latest Key Developments (Source: Significant Developments)

Vanda Pharma settles Fanapt patent litigation with Apotex
Wednesday, 7 Dec 2016 06:45pm EST 

Vanda Pharmaceuticals Inc : Vanda Pharmaceuticals settles Fanapt® patent litigation with Apotex .Agreement provides for full settlement and release by Vanda and Apotex of all claims that are subject of litigation.  Full Article

Vanda says U.S. District Court ruled Roxane Laboratories infringed certain patents
Thursday, 25 Aug 2016 02:51pm EDT 

Vanda Pharmaceuticals Inc :U.S. District Court ruled that Roxane Laboratories infringed U.S. patent nos. RE39,198 and 8,586,610 by submitting to FDA an ANDA.  Full Article

Vanda Pharmaceuticals Q2 loss per share $0.11
Wednesday, 27 Jul 2016 04:01pm EDT 

Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says reiterates its prior 2016 financial guidance . Hetlioz net product sales grew to $17.5 million , fanapt net product sales grew to $18.6 million in q2 2016 .Says year end 2016 cash is expected to be between $123 and $143 million.  Full Article

Vanda says FDA approved NDA for drug to treat schizophrenia in adults
Thursday, 26 May 2016 04:30pm EDT 

Vanda Pharmaceuticals Inc : New approved PI now includes placebo-controlled, long-term study data .Vanda announces FDA approval of the Fanapt supplemental new drug application for maintenance treatment of schizophrenia in adults.  Full Article

Vanda Pharmaceuticals Inc accepts Fanaptum Marketing authorization application for treatment of Schizophrenia in adults
Tuesday, 22 Dec 2015 04:30pm EST 

Vanda Pharmaceuticals Inc:Says Marketing Authorization Application for oral Fanaptum tablets has been accepted for evaluation by European Medicines Agency for treatment of schizophrenia in adults.  Full Article

Vanda Pharmaceuticals Inc reaffirms FY 2015 net product sales guidance
Tuesday, 3 Nov 2015 04:01pm EST 

Vanda Pharmaceuticals Inc:Affirms its FY 2015 net product sales guidance of between $100 million and $115 million.FY 2015 revenue of $112 million - Thomson Reuters I/B/E/S.  Full Article

Vanda Announces FDA Has Accepted for Review the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults
Tuesday, 15 Sep 2015 07:00am EDT 

Vanda Pharmaceuticals Inc:Announces that the U.S. Food and Drug Administration (FDA) has accepted for review Vanda's filing of a supplemental New Drug Application (sNDA) for Fanapt seeking approval as a maintenance treatment of schizophrenia in adults.  Full Article

Vanda Pharmaceuticals Inc's Hetlioz receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind
Tuesday, 7 Jul 2015 04:30pm EDT 

Vanda Pharmaceuticals Inc:Announced that the European Commission (EC) approved HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union.  Full Article

Vanda reports positive results from relapse prevention study in schizophrenia patients
Tuesday, 23 Jun 2015 04:30pm EDT 

Vanda Pharmaceuticals Inc:Announces positive results from the relapse prevention study in patients with schizophrenia (reprieve) demonstrating the long-term maintenance effects of fanapt (iloperidone).Intends to file supplemental new drug application for fanapt with the U.S. FDA in second half of 2015.In reprieve study, 79.6% of patients treated with fanapt remained relapse free compared to 36.6% for placebo-treated patients.Reprieve study demonstrated ability of fanapt to prevent relapse, impending relapse in adult patients with schizophrenia versus placebo.  Full Article

Vanda Pharmaceuticals receives positive CHMP opinion for HETLIOZ (tasimelteon)
Friday, 24 Apr 2015 07:44am EDT 

Vanda Pharmaceuticals:Says the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union (EU).The CHMP positive opinion will be reviewed by the European Commission (EC).  Full Article

More From Around the Web

BRIEF-Point72 Asset Management reports 5 pct passive stake in Vanda Pharmaceuticals as of Feb 15 - SEC Filing

* Point72 Asset Management Reports 5 pct passive stake in Vanda Pharmaceuticals Inc as of Feb 15 - SEC Filing Source text: [http://bit.ly/2lnm4r7] Further company coverage: